Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BWAYNYSE:CATXNASDAQ:CTCXNASDAQ:INGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBWAYBrainsWay$10.31-1.2%$9.23$5.67▼$11.79$194.57M1.2567,648 shs21,175 shsCATXPerspective Therapeutics$2.57-4.8%$2.25$1.60▼$16.55$190.77M1.111.03 million shs587,171 shsCTCXCarmell$3.30-11.8%$0.83$0.17▼$2.65$68.99M0.513.80 million shs269,807 shsINGNInogen$6.44-1.4%$6.78$5.70▼$13.33$173.15M1.63238,976 shs123,308 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBWAYBrainsWay0.00%-3.91%+14.30%+10.39%+63.91%CATXPerspective Therapeutics0.00%+7.53%+0.39%+4.47%-81.38%CTCXCarmell0.00%+38.66%+1,780.34%+1,362.77%+32.53%INGNInogen0.00%-1.38%-10.56%-20.79%-22.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBWAYBrainsWay2.9363 of 5 stars3.53.00.00.02.20.81.9CATXPerspective Therapeutics3.506 of 5 stars4.60.00.00.02.72.50.6CTCXCarmellN/AN/AN/AN/AN/AN/AN/AN/AINGNInogen4.0824 of 5 stars3.03.00.03.92.81.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBWAYBrainsWay 3.00Buy$14.2538.22% UpsideCATXPerspective Therapeutics 3.18Buy$12.50386.38% UpsideCTCXCarmell 0.00N/AN/AN/AINGNInogen 2.00Hold$9.5047.52% UpsideCurrent Analyst Ratings BreakdownLatest CTCX, BWAY, CATX, and INGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025INGNInogenNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Moderate Buy$12.005/14/2025CATXPerspective TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $8.005/13/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.005/8/2025INGNInogenStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$10.00 ➝ $7.004/9/2025INGNInogenNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/7/2025CATXPerspective TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $10.003/31/2025CATXPerspective TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/27/2025CATXPerspective TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$16.00 ➝ $15.003/26/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00 ➝ $11.003/19/2025CATXPerspective TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/17/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBWAYBrainsWay$43.46M4.48N/AN/A$2.50 per share4.12CATXPerspective Therapeutics$1.43M133.40N/AN/A$2.67 per share0.96CTCXCarmell$32.84K2,100.75N/AN/A$1.07 per share3.08INGNInogen$339.96M0.51N/AN/A$8.79 per share0.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBWAYBrainsWay-$4.20M$0.20103.1164.44N/A3.88%3.52%2.26%8/5/2025 (Estimated)CATXPerspective Therapeutics-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%8/11/2025 (Estimated)CTCXCarmell-$15.44MN/A0.00∞N/AN/A-217.50%-50.22%N/AINGNInogen-$102.45M-$1.15N/AN/AN/A-15.89%-27.38%-16.77%8/5/2025 (Estimated)Latest CTCX, BWAY, CATX, and INGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025BWAYBrainsWay$0.02$0.04+$0.02$0.04$11.45 million$11.54 million5/7/2025Q1 2025INGNInogen-$0.52-$0.25+$0.27-$0.25$79.57 million$82.28 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBWAYBrainsWayN/AN/AN/AN/AN/ACATXPerspective TherapeuticsN/AN/AN/AN/AN/ACTCXCarmellN/AN/AN/AN/AN/AINGNInogenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBWAYBrainsWayN/A4.524.23CATXPerspective TherapeuticsN/A9.609.60CTCXCarmellN/A0.310.29INGNInogenN/A2.662.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBWAYBrainsWay30.11%CATXPerspective Therapeutics54.66%CTCXCarmell24.22%INGNInogen89.94%Insider OwnershipCompanyInsider OwnershipBWAYBrainsWay19.00%CATXPerspective Therapeutics3.72%CTCXCarmell29.00%INGNInogen1.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBWAYBrainsWay12018.87 million15.24 millionNot OptionableCATXPerspective Therapeutics7074.23 million65.21 millionOptionableCTCXCarmell1420.91 million14.84 millionNot OptionableINGNInogen1,03026.89 million23.58 millionOptionableCTCX, BWAY, CATX, and INGN HeadlinesRecent News About These CompaniesWith 72% ownership of the shares, Inogen, Inc. (NASDAQ:INGN) is heavily dominated by institutional ownersMay 30 at 7:59 PM | finance.yahoo.comHere's Why You Should Add Inogen Stock to Your Portfolio NowMay 28, 2025 | zacks.comZacks.com featured highlights Urban Outfitters, Inogen and Southwest GasMay 28, 2025 | finance.yahoo.com3 Stocks With Upgraded Broker Ratings to Bet on Amid UncertaintiesMay 27, 2025 | zacks.comD. E. Shaw & Co. Inc. Sells 77,489 Shares of Inogen, Inc. (NASDAQ:INGN)May 26, 2025 | marketbeat.comInogen shares upgraded to Buy at Needham, $12 price target setMay 24, 2025 | uk.investing.comInogen (NASDAQ:INGN) Stock Rating Upgraded by Needham & Company LLCMay 24, 2025 | marketbeat.comNeedham Upgrades Inogen (INGN) to BuyMay 23, 2025 | finance.yahoo.comNeedham Upgrades Inogen (INGN)May 23, 2025 | msn.comNeedham Upgrades Inogen (INGN) to BuyMay 23, 2025 | msn.comInogen Upgraded: Analyst Sees Growth, EBITDA BreakthroughMay 22, 2025 | benzinga.comThis United Rentals Analyst Turns Bullish; Here Are Top 5 Upgrades For ThursdayMay 22, 2025 | benzinga.comInogen Approves 2023 Equity Incentive Plan ExpansionMay 19, 2025 | tipranks.comWhat Makes Inogen (INGN) a New Buy StockMay 16, 2025 | zacks.comAfter Plunging -15.69% in 4 Weeks, Here's Why the Trend Might Reverse for Inogen (INGN)May 16, 2025 | zacks.comCubist Systematic Strategies LLC Raises Stock Position in Inogen, Inc. (NASDAQ:INGN)May 16, 2025 | marketbeat.comDimensional Fund Advisors LP Buys 123,208 Shares of Inogen, Inc. (NASDAQ:INGN)May 15, 2025 | marketbeat.comFred Alger Management LLC Has $5.51 Million Holdings in Inogen, Inc. (NASDAQ:INGN)May 12, 2025 | marketbeat.comCompanies Like Inogen (NASDAQ:INGN) Can Afford To Invest In GrowthMay 10, 2025 | finance.yahoo.comInogen: ‘We are making great progress’May 9, 2025 | hmenews.comEarnings call transcript: Inogen sees Q1 2025 revenue rise, stock up 3.91%May 9, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCTCX, BWAY, CATX, and INGN Company DescriptionsBrainsWay NASDAQ:BWAY$10.31 -0.12 (-1.15%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$10.20 -0.11 (-1.07%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.Perspective Therapeutics NYSE:CATX$2.57 -0.13 (-4.81%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$2.57 0.00 (0.00%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.Carmell NASDAQ:CTCX$3.30 -0.44 (-11.76%) As of 05/30/2025Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.Inogen NASDAQ:INGN$6.44 -0.09 (-1.38%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$6.42 -0.02 (-0.23%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Apple’s Quiet HomePad Delay Could Be Its Loudest Move Yet Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
